These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36274381)

  • 1. Genetics and epigenetics in conventional chondrosarcoma with focus on non-coding RNAs.
    Roessner A; Franke S; Schreier J; Ullmann S; Karras F; Jechorek D
    Pathol Res Pract; 2022 Nov; 239():154172. PubMed ID: 36274381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isocitrate dehydrogenase mutations in chondrosarcoma: the crossroads between cellular metabolism and oncogenesis.
    Azzi G; Velez M; Mathias-Machado MC
    Curr Opin Oncol; 2014 Jul; 26(4):403-7. PubMed ID: 24867810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
    Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
    Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling.
    M Gagné L; Boulay K; Topisirovic I; Huot MÉ; Mallette FA
    Trends Cell Biol; 2017 Oct; 27(10):738-752. PubMed ID: 28711227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
    Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
    PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
    Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
    Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth.
    Li L; Hu X; Eid JE; Rosenberg AE; Wilky BA; Ban Y; Sun X; Galoian K; DeSalvo J; Yue J; Chen XS; Blonska M; Trent JC
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31935911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract.
    Tallegas M; Miquelestorena-Standley É; Labit-Bouvier C; Badoual C; Francois A; Gomez-Brouchet A; Aubert S; Collin C; Tallet A; de Pinieux G
    Hum Pathol; 2019 Feb; 84():183-191. PubMed ID: 30296521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct IDH1/2-associated Methylation Profile and Enrichment of
    Dermawan JKT; Nafa K; Mohanty A; Xu Y; Rijo I; Casanova J; Villafania L; Benhamida J; Kelly CM; Tap WD; Boland PJ; Fabbri N; Healey JH; Ladanyi M; Lu C; Hameed M
    Cancer Res Commun; 2023 Mar; 3(3):431-443. PubMed ID: 36926116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
    Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
    Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
    Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
    Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct Roles of Glutamine Metabolism in Benign and Malignant Cartilage Tumors With IDH Mutations.
    Zhang H; Puviindran V; Nadesan P; Ding X; Shen L; Tang YJ; Tsushima H; Yahara Y; Ban GI; Zhang GF; Karner CM; Alman BA
    J Bone Miner Res; 2022 May; 37(5):983-996. PubMed ID: 35220602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Profiling Identifies Association of
    Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
    Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia Induces Production of L-2-Hydroxyglutarate.
    Intlekofer AM; Dematteo RG; Venneti S; Finley LW; Lu C; Judkins AR; Rustenburg AS; Grinaway PB; Chodera JD; Cross JR; Thompson CB
    Cell Metab; 2015 Aug; 22(2):304-11. PubMed ID: 26212717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
    Amary MF; Bacsi K; Maggiani F; Damato S; Halai D; Berisha F; Pollock R; O'Donnell P; Grigoriadis A; Diss T; Eskandarpour M; Presneau N; Hogendoorn PC; Futreal A; Tirabosco R; Flanagan AM
    J Pathol; 2011 Jul; 224(3):334-43. PubMed ID: 21598255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
    Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
    Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocitrate dehydrogenase mutations in gliomas.
    Waitkus MS; Diplas BH; Yan H
    Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma.
    Venneker S; Szuhai K; Hogendoorn PCW; Bovée JVMG
    Virchows Arch; 2020 Jan; 476(1):135-146. PubMed ID: 31728625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.